对MARS2试验的视角
本文汇集国际知名胸膜间皮瘤专家,对比较扩展胸膜切除剥脱术联合化疗与单纯化疗的3期随机对照试验MARS2进行解读,专家意见分为认同试验解释与质疑试验实施影响结果两方,讨论随机化、质量保证、组织学亚型选择、随机化时机、术前分期、统计方法和手术死亡率等议题,结论认为未来手术决策仍由共识指南和支付方意愿决定。
要点
- MARS2报告可切除胸膜间皮瘤患者中扩展胸膜切除剥脱术联合化疗较单纯化疗2年生存更差且严重不良事件更多。
- 间皮瘤外科界对MARS2解读未达成一致,专家就随机化、质量保证、组织学亚型选择、随机化时机、术前分期、统计方法和手术死亡率展开辩论。
- 未来胸膜间皮瘤手术决策将继续由共识指南和健康支付方意愿界定,MARS2的解读可能影响手术角色。
核心结论
- 未来胸膜间皮瘤手术决策将继续由共识指南和健康支付方意愿界定,MARS2的解读可能对手术角色起重要调节作用。
研究设计与样本
- 本文为视角性文章,由协调者与团队负责人组织国际知名胸膜间皮瘤专家,在全文发表后分别撰写认同或不认同试验解释的论据,再合并稿件供各团队编辑。
主要发现
- 专家论点涵盖随机化的困难与优势、质量保证、组织学亚型选择、随机化时机、术前分期使用、统计方法及手术死亡率原因。
- MARS2报告扩展胸膜切除剥脱术联合化疗与单纯化疗相比,可切除胸膜间皮瘤患者2年生存更差且严重不良事件更多。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported "extended pleurectomy decortication was associated with worse survival to 2 years, and more serious adverse events for individuals with resectable PM, compared with chemotherapy alone." These results have led to considerable discourse regarding the future role of surgery for PM, and there has not been unanimity in the mesothelioma surgical community regarding the trial interpretation. This "perspective" evaluates MARS2 using internationally renowned PM experts who either agreed with the trial interpretation or who found issues with its conduct which may have influenced the results. METHODS: A facilitator (HP) worked with team leaders (GW, IO) to assemble individuals offering opinions regarding the trial and its conclusions. Arguments agreeing or not agreeing with the trial interpretation were written only after publication of the full trial. Once both arguments were received by the facilitator, the individual team manuscripts were combined and sent to each team allowing editing for changes in perceived factual errors. FINDINGS: Insightful arguments include (but were not limited to) the difficulties yet advantages of randomization, quality assurance, selection of histologic subtypes, the timing of randomization, use of preoperative staging, statistical methods, and reasons for surgical mortality. CONCLUSIONS: The decision to operate for PM in the future will continue to be defined by consensus guidelines and health payer willingness, and the interpretation of MARS2 may play an important role in modulating the role of surgery in the future.
引用
- Lim E, Opitz I, Woodard G, et al. A Perspective on the MARS2 Trial. J Thorac Oncol. 2025. PMID: 39772349. doi:10.1016/j.jtho.2024.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。